BTK Inhibitors and the Genomic Shift in CLL

Автор: Blood Cancers Today

Загружено: 2025-12-20

Просмотров: 95

Описание: Moderated by Tycel Phillips, MD, of City of Hope National Medical Center, a panel of experts discuss the evolving genomic and therapeutic landscape of chronic lymphocytic leukemia (CLL) during a Blood Cancers Today Roundtable. The discussion features Seema Bhat, MD, of The Ohio State University; Erin Mulvey, MD, of Weill Cornell Medicine; Danielle Brander, MD, of Duke Cancer Institute; and Andres Chang, MD, PhD, of the Winship Cancer Institute at Emory University.

Watch more like this at www.bloodcancerstoday.com

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...

BTK Inhibitors and the Genomic Shift in CLL

Доступные форматы для скачивания:

Скачать видео

Информация по загрузке:

Скачать аудио

Похожие видео

Research Powering the Next Era of CLL Therapy

Research Powering the Next Era of CLL Therapy

Modern Targeted Treatment Strategies in CLL

Modern Targeted Treatment Strategies in CLL

The Fight Against Myeloid Malignancies: Early Warning Signs and Emerging Innovations

The Fight Against Myeloid Malignancies: Early Warning Signs and Emerging Innovations

CLL Year in Review: Zanubrutinib, Venetoclax, and the Shifting Treatment Landscape

CLL Year in Review: Zanubrutinib, Venetoclax, and the Shifting Treatment Landscape

Caitlin Franchini Interview | Stuttering and SLP Advocacy

Caitlin Franchini Interview | Stuttering and SLP Advocacy

Orędzie noworoczne Prezydenta RP

Orędzie noworoczne Prezydenta RP

ТАК БОЛЬШЕ НЕ БУДУТ ЛЕЧИТЬ В 2026 ГОДУ? Революционные изменения в кардиологии

ТАК БОЛЬШЕ НЕ БУДУТ ЛЕЧИТЬ В 2026 ГОДУ? Революционные изменения в кардиологии

The Role of XPO1 Inhibition From Early to Advanced Myeloma

The Role of XPO1 Inhibition From Early to Advanced Myeloma

Из-за этого мало кто доживает до 70! Вся правда про нижнее давление!

Из-за этого мало кто доживает до 70! Вся правда про нижнее давление!

Potential risks of hair relaxers | Damage Control

Potential risks of hair relaxers | Damage Control

How do you approach a patient with POD24 in follicular lymphoma?

How do you approach a patient with POD24 in follicular lymphoma?

What’s Your Plan? Seizure Clusters and Rescue Medications

What’s Your Plan? Seizure Clusters and Rescue Medications

Treating and Managing Chronic Lymphocytic Leukemia (CLL) in 2025: Dr. Mazyar Shadman

Treating and Managing Chronic Lymphocytic Leukemia (CLL) in 2025: Dr. Mazyar Shadman

Как расшифровать геном человека — Марк Дж. Киел

Как расшифровать геном человека — Марк Дж. Киел

BTK Degraders for CLL

BTK Degraders for CLL

IGHV-Mutated vs IGHV-Unmutated CLL | What’s the Difference?

IGHV-Mutated vs IGHV-Unmutated CLL | What’s the Difference?

Dr. Robert Orlowski Shares Linvoseltamab Benefits in Frontline Multiple Myeloma

Dr. Robert Orlowski Shares Linvoseltamab Benefits in Frontline Multiple Myeloma

Kimberly Manning, MD, describes how racism affects the health care system

Kimberly Manning, MD, describes how racism affects the health care system

Why Toxicity and Time Matter in Blood Cancer Care

Why Toxicity and Time Matter in Blood Cancer Care

Jean-Marie Michot, MD, Shares Olympia-3 Insights on Odronextamab Plus Chemotherapy in DLBCL

Jean-Marie Michot, MD, Shares Olympia-3 Insights on Odronextamab Plus Chemotherapy in DLBCL